Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 33

1.

Cannabidiol Treatment in a Murine Model of Systemic Lupus Erythematosus Accelerates Proteinuria Development.

Katz-Talmor D, Kivity S, Blank M, Katz I, Perry O, Volkov A, Barshack I, Amital H, Shoenfeld Y.

Isr Med Assoc J. 2018 Dec;20(12):741-745. No abstract available.

2.

Avidekel Cannabis extracts and cannabidiol are as efficient as Copaxone in suppressing EAE in SJL/J mice.

Gallily R, Yekhtin Z.

Inflammopharmacology. 2018 Oct 5. doi: 10.1007/s10787-018-0536-3. [Epub ahead of print]

PMID:
30291491
3.

Variability of Multiple Sclerosis Spasticity Symptoms in Response to THC:CBD Oromucosal Spray: Tracking Cases through Clinical Scales and Video Recordings.

Flachenecker P, Saccà F, Vila C.

Case Rep Neurol. 2018 Jul 12;10(2):169-176. doi: 10.1159/000490376. eCollection 2018 May-Aug.

4.

Cannabidiol Attenuates Experimental Autoimmune Encephalomyelitis Model of Multiple Sclerosis Through Induction of Myeloid-Derived Suppressor Cells.

Elliott DM, Singh N, Nagarkatti M, Nagarkatti PS.

Front Immunol. 2018 Aug 3;9:1782. doi: 10.3389/fimmu.2018.01782. eCollection 2018.

5.

The Role of Cannabis within an Emerging Perspective on Schizophrenia.

Diviant JP, Vigil JM, Stith SS.

Medicines (Basel). 2018 Aug 8;5(3). pii: E86. doi: 10.3390/medicines5030086.

6.

EHP-101, an oral formulation of the cannabidiol aminoquinone VCE-004.8, alleviates bleomycin-induced skin and lung fibrosis.

García-Martín A, Garrido-Rodríguez M, Navarrete C, Del Río C, Bellido ML, Appendino G, Calzado MA, Muñoz E.

Biochem Pharmacol. 2018 Nov;157:304-313. doi: 10.1016/j.bcp.2018.07.047. Epub 2018 Aug 2.

PMID:
30076848
7.

Hypoxia mimetic activity of VCE-004.8, a cannabidiol quinone derivative: implications for multiple sclerosis therapy.

Navarrete C, Carrillo-Salinas F, Palomares B, Mecha M, Jiménez-Jiménez C, Mestre L, Feliú A, Bellido ML, Fiebich BL, Appendino G, Calzado MA, Guaza C, Muñoz E.

J Neuroinflammation. 2018 Mar 1;15(1):64. doi: 10.1186/s12974-018-1103-y.

8.

Oral administration of cannabis with lipids leads to high levels of cannabinoids in the intestinal lymphatic system and prominent immunomodulation.

Zgair A, Lee JB, Wong JCM, Taha DA, Aram J, Di Virgilio D, McArthur JW, Cheng YK, Hennig IM, Barrett DA, Fischer PM, Constantinescu CS, Gershkovich P.

Sci Rep. 2017 Nov 6;7(1):14542. doi: 10.1038/s41598-017-15026-z.

9.

Mechanisms of action of cannabidiol in adoptively transferred experimental autoimmune encephalomyelitis.

González-García C, Torres IM, García-Hernández R, Campos-Ruíz L, Esparragoza LR, Coronado MJ, Grande AG, García-Merino A, Sánchez López AJ.

Exp Neurol. 2017 Dec;298(Pt A):57-67. doi: 10.1016/j.expneurol.2017.08.017. Epub 2017 Sep 1.

PMID:
28867485
10.

Cannabidiol as a Therapy for ASIA Syndrome? An Editorial on a Novel Study.

Katz D, Shoenfeld Y.

Isr Med Assoc J. 2017 Feb;19(2):98-99. No abstract available.

11.

Target regulation of PI3K/Akt/mTOR pathway by cannabidiol in treatment of experimental multiple sclerosis.

Giacoppo S, Pollastro F, Grassi G, Bramanti P, Mazzon E.

Fitoterapia. 2017 Jan;116:77-84. doi: 10.1016/j.fitote.2016.11.010. Epub 2016 Nov 25.

PMID:
27890794
12.

Cannabidiol: a potential treatment for post Ebola syndrome?

Reznik SE, Gardner EL, Ashby CR Jr.

Int J Infect Dis. 2016 Nov;52:74-76. doi: 10.1016/j.ijid.2016.09.020. Epub 2016 Sep 26.

13.

Pathways and gene networks mediating the regulatory effects of cannabidiol, a nonpsychoactive cannabinoid, in autoimmune T cells.

Kozela E, Juknat A, Gao F, Kaushansky N, Coppola G, Vogel Z.

J Neuroinflammation. 2016 Jun 3;13(1):136. doi: 10.1186/s12974-016-0603-x.

14.

Cannabidiol Limits T Cell-Mediated Chronic Autoimmune Myocarditis: Implications to Autoimmune Disorders and Organ Transplantation.

Lee WS, Erdelyi K, Matyas C, Mukhopadhyay P, Varga ZV, Liaudet L, Haskú G, Čiháková D, Mechoulam R, Pacher P.

Mol Med. 2016 Sep;22:136-146. doi: 10.2119/molmed.2016.00007. Epub 2016 Jan 8.

15.

Purified Cannabidiol, the main non-psychotropic component of Cannabis sativa, alone, counteracts neuronal apoptosis in experimental multiple sclerosis.

Giacoppo S, Soundara Rajan T, Galuppo M, Pollastro F, Grassi G, Bramanti P, Mazzon E.

Eur Rev Med Pharmacol Sci. 2015 Dec;19(24):4906-19.

16.

The disease-modifying effects of a Sativex-like combination of phytocannabinoids in mice with experimental autoimmune encephalomyelitis are preferentially due to Δ9-tetrahydrocannabinol acting through CB1 receptors.

Moreno-Martet M, Feliú A, Espejo-Porras F, Mecha M, Carrillo-Salinas FJ, Fernández-Ruiz J, Guaza C, de Lago E.

Mult Scler Relat Disord. 2015 Nov;4(6):505-11. doi: 10.1016/j.msard.2015.08.001. Epub 2015 Aug 5.

PMID:
26590655
17.

A new formulation of cannabidiol in cream shows therapeutic effects in a mouse model of experimental autoimmune encephalomyelitis.

Giacoppo S, Galuppo M, Pollastro F, Grassi G, Bramanti P, Mazzon E.

Daru. 2015 Oct 21;23:48. doi: 10.1186/s40199-015-0131-8.

18.

HU-446 and HU-465, Derivatives of the Non-psychoactive Cannabinoid Cannabidiol, Decrease the Activation of Encephalitogenic T Cells.

Kozela E, Haj C, Hanuš L, Chourasia M, Shurki A, Juknat A, Kaushansky N, Mechoulam R, Vogel Z.

Chem Biol Drug Des. 2016 Jan;87(1):143-53. doi: 10.1111/cbdd.12637. Epub 2015 Sep 16.

PMID:
26259697
19.

Cannabidiol, a non-psychoactive cannabinoid, leads to EGR2-dependent anergy in activated encephalitogenic T cells.

Kozela E, Juknat A, Kaushansky N, Ben-Nun A, Coppola G, Vogel Z.

J Neuroinflammation. 2015 Mar 15;12:52. doi: 10.1186/s12974-015-0273-0.

20.

Interaction between the protective effects of cannabidiol and palmitoylethanolamide in experimental model of multiple sclerosis in C57BL/6 mice.

Rahimi A, Faizi M, Talebi F, Noorbakhsh F, Kahrizi F, Naderi N.

Neuroscience. 2015 Apr 2;290:279-87. doi: 10.1016/j.neuroscience.2015.01.030. Epub 2015 Jan 28.

PMID:
25637488

Supplemental Content

Loading ...
Support Center